Video Library

A recent Science study reveals that a single mutation in the H5N1 “bird flu” virus could enhance the virus’ ability to attach to human cells. Led by Scripps Research scientists Ian Wilson and James Paulson, the study highlights the need to monitor H5N1’s evolution.

On November 10, 2024, Scripps Research continued its year of centennial celebrations with an afternoon of interactive discovery at the Fleet Science Center in San Diego’s Balboa Park. The event coincided with the annual World Science Day for Peace and Development and highlighted the renowned institute’s 100-year anniversary.

Scripps Research leadership, philanthropists and scientists celebrated the recent dedication of the new Chi-Huey Wong Laboratories for Biomedical Research on October 23, 2024, with a special ribbon-cutting ceremony and reception. Philanthropic support from several donors made this exciting addition to Scripps Research’s award-winning Hazen campus possible. Notably, Samuel Yin, Taiwanese businessman, prominent philanthropist and creator of the Tang Prize, provided generous seed funding to construct the new facility. His son, Chung-Yao Yin, attended the event and delivered remarks on his father’s behalf. Professor Chi-Huey Wong, the building’s namesake, also attended, as well as Scripps Research supporter Jim Zolin, who named the building’s first-floor conference room. The state-of-the-art Chi-Huey Wong Laboratories is one of the largest facilities built by the institute and marks a significant milestone in Scripps Research’s efforts to enable interdisciplinary collaborations across chemical and life sciences.

The mitochondria are well known for being cellular “powerhouses,” given their important role in energy generation. Yet emerging research is now suggesting these organelles also play a key role as the stress-sensors for the cell. In this Front Row lecture, Scripps Research assistant professor Danielle Grotjahn explored how mitochondria change shape in response to different genetic and environmental stressors. By harnessing cutting-edge imaging technologies to examine mitochondria in these never-before-seen-ways, Grotjahn is revealing how these organelles can predict overall cellular health and even disease, including neurodegenerative disorders and cancer.

The Calibr-Skaggs Institute for Innovative Medicines, part of Scripps Research, has begun testing a new regenerative lung therapy called CMR316. This inhaled treatment could change the way we treat lung diseases like idiopathic pulmonary fibrosis (IPF) and potentially even chronic obstructive pulmonary disease by stimulating stem cells to restore damaged lung tissue. In this phase 1 clinical trial, they're checking the safety and effects of this once-weekly drug in both healthy volunteers and IPF patients.

The inner workings of the brain have eluded neuroscientists for ages—including how we perceive sensations such as touch, pain, sound and even blood flow. In this Front Row lecture, Scripps Research professor and Nobel laureate Ardem Patapoutian discussed the molecular sensors that enable the mind to interpret different physical and chemical stimuli. These discoveries—for which Patapoutian was awarded the 2021 Nobel Prize in Physiology or Medicine—are helping answer long-standing questions in neuroscience, such as how cells communicate with each other, how we sense our body in time and space, how these sensors impact different diseases and more.

The Skaggs Graduate School of Chemical and Biological Sciences at Scripps Research offers a top-10 ranked doctoral program that empowers graduate students to make high-impact discoveries at the interface of chemistry and biology. Roughly 400 PhD students, both in La Jolla, California, and Jupiter, Florida, are currently enrolled in the program, working with almost 150 graduate program faculty members. Almost 1,000 students have earned doctoral degrees from the program since its inception in 1989. The Skaggs Graduate School immerses doctoral students in intensive laboratory research from day one. World-renowned faculty impart knowledge and expertise as mentors and advisors. Students customize their course curriculum to match individual research interests while exploring multidisciplinary topics across the spectrum of chemistry and biology.

Students, faculty, and leadership from seven institutions across the west came together at Scripps Research for the 2024 Skaggs Biomedical Research Symposium—a celebration of life-changing innovations originating from our labs. Throughout three days of oral presentations, poster sessions and networking, participants shared and explored the groundbreaking science made possible by the generosity of the Skaggs family.

Why are donations important in empowering the future leaders of science? As a nonprofit organization, Scripps Research relies on generous contributions from individuals, foundations and corporations to support our many biomedical research and educational programs, including our top-10 ranked doctoral program. The most impactful and enduring of these contributions came from the Skaggs family, who have a long and storied history of supporting nonprofit biomedical research and education programs across the western United States. In 2018, Scripps Research announced that the Skaggs family made a lead gift through The ALSAM Foundation toward the institute’s $100 million campaign to establish endowed fellowships for students in its Graduate Program. In honor of this gift, the program was renamed the Skaggs Graduate School of Chemical and Biological Sciences.

Infectious diseases like tuberculosis and malaria pose an ever-increasing risk to communities around the world. Meanwhile, a lack of investment, long treatment protocols and drug resistance have stymied innovation in this area. In this Front Row lecture, Vice President of Medicinal Chemistry Arnab Chatterjee discussed how the Calibr-Skaggs Institute of Innovative Medicines—the drug discovery and development arm of Scripps Research—is using innovative new approaches and technologies to overcome these historic barriers. His work at the Calibr-Skaggs Institute is helping accelerate the delivery of safe, effective and accessible medicines to countries spanning the globe.

Regenerative medicine involves harnessing the body’s own capacity to repair tissues and organs. In this Front Row lecture, Associate Professor Michael Bollong shared how he's identifying and targeting the pathways controlling regeneration. By combining traditional drug discovery tools with modern biological techniques, Bollong and his lab are developing novel medicines that can intervene in the processes that cause a spectrum of human diseases and medical conditions, including heart disease, inflammatory disease and fibrosis.

Some neurocognitive diseases, such as Alzheimer’s disease and other dementias, affect more women than men. There are also gaps in our understanding of the impact of sleep on women’s cognitive health. Scientists at the Scripps Research Digital Trials Center have launched the REFRESH- Neurocognitive Outcomes in Women study (REFRESH-NOW), a new research project aimed at better understanding sleep and brain health in women with the help of fitness trackers. REFRESH-NOW, led by Stuti Jaiswal, a physician-scientist specializing in sleep research, will use wrist-worn activity trackers and smartwatches to gather longitudinal data from women who are 55 and older over a three-year period. The goal of the study is to identify sleep-related risk factors, enabling for the development of better interventions.

Originally from the Antelope Valley, Alex's journey from her hometown to the renowned Scripps Research in La Jolla is a testament to perseverance and passion. From growing up in an underserved neighborhood to researching alongside a Nobel Laureate, she’s proving that anyone can become a researcher and help shape the future.

Checkpoint inhibitor therapies can be thought of as the molecular “brake release” for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and targeting cancer cells in the body. While there are multiple checkpoint inhibitors approved to treat different types of cancer, many patients don’t respond or develop resistance to available regiments. A Scripps Research team has now found that ruxolitinib, an approved immunosuppressive drug, supercharged T-cell responses when used alongside checkpoint inhibitors—boosting their effectiveness in fighting cancer. These findings, published in Science on June 21, are supported by a phase I clinical trial of patients with Hodgkin lymphoma, as well as preclinical models.

Embark on a journey into the heart of scientific breakthroughs with Scripps Research. From the frontier of artificial intelligence to pioneering precision medicines, our postdocs, grad students and junior faculty are paving the way for transformative advancements in healthcare, climate science and beyond.

Embark on a journey into the heart of scientific breakthroughs with Scripps Research. From the frontier of artificial intelligence to pioneering precision medicines, our postdocs, grad students and junior faculty are paving the way for transformative advancements in healthcare, climate science and beyond.

Embark on a journey into the heart of scientific breakthroughs with Scripps Research. From the frontier of artificial intelligence to pioneering precision medicines, our postdocs, grad students and junior faculty are paving the way for transformative advancements in healthcare, climate science and beyond.

In May 2024, Scripps Research's Skaggs Graduate School awarded doctoral degrees to its 32nd graduating class. Professors and faculty share their wisdom to the 59 students who graduated. Among "be bold, be curious and take the world by the horns," hear what else they had to say.

The Skaggs Graduate School of Chemical and Biological Sciences at Scripps Research is pleased to present our 2024 Commencement Ceremony, celebrating our 59 newest doctoral degree recipients who comprise Scripps Research’s 32nd graduating class. Held on Friday, May 17, 2024, the event featured introductions of the graduating students by their faculty mentors, recognizing their academic achievements and scientific accomplishments, as well as a keynote address by noted chemist and Scripps Research alumnus Phil Baran. We hope you enjoy this celebration of research and discovery, as well as the tenacity, creativity and incredible promise demonstrated by these young scientists.

All proteins have a correct way of “folding” themselves into their 3D structures. When this folding process goes awry, including processes leading to protein misassembly, a number of devastating diseases can result. In this Front Row lecture, Scripps Research professor Jeffery Kelly shared how he's developing novel therapeutic strategies to target these protein misfolding diseases, which lead to deterioration of the heart and brain. His multi-disciplinary research has already led to the development of an FDA-approved drug available in the pharmacy called tafamidis (Vyndaqel® and Vyndamax®): a medicine that slows the progression of the neurodegenerative disease familial amyloid polyneuropathy and the degenerative heart disease called TTR cardiomyopathy.

Scripps Research professor Jeffery Kelly received an unexpected visit from a patient whose life was dramatically improved by tafamidis—a revolutionary drug for treating neurodegenerative and heart diseases, developed by Kelly himself. Kelly is a leading figure at Scripps Research, spearheading efforts to address some of the most pressing medical challenges, including Alzheimer’s and various amyloid diseases. His cutting-edge research on protein misfolding has not only led to the development of tafamidis but has also broadened our understanding of protein aggregation disorders.

Scripps Research professor Jeffery Kelly received an unexpected visit from a patient whose life was dramatically improved by tafamidis—a revolutionary drug for treating neurodegenerative and heart diseases, developed by Kelly himself. Kelly is a leading figure at Scripps Research, spearheading efforts to address some of the most pressing medical challenges, including Alzheimer’s and various amyloid diseases. His cutting-edge research on protein misfolding has not only led to the development of tafamidis but has also broadened our understanding of protein aggregation disorders.

Scripps Research scientists have discovered how long chains of molecules called polyphosphates (polyP) are needed for bacteria to slow down movements within cells and let them enter a resting state. This “resting state” helps the pathogen evade antibiotics and contributes to severe chronic infections in the lungs and blood, within wounds, and on the surfaces of medical devices. These findings, published in Proceedings of the National Academy of Sciences on April 02, 2024, could eventually lead to new ways of treating chronic infections in which typical antibiotics aren’t effective.

Mental disorders like depression and schizophrenia affect the lives of millions of people around the world, and yet, available treatment options have remained the same for decades. In this Front Row lecture, Scripps Research professor Hugh Rosen shared how his pioneering research has led to the development of the drug navacaprant, which precisely targets one of the brain’s behavioral circuits and is currently in clinical testing for major depressive disorder. Harnessing his expertise as a physician-scientist, Rosen has discovered and developed multiple other medicines, including ozanimod—a breakthrough treatment approved for multiple sclerosis and ulcerative colitis.

On February 15, 2024, Scripps Research celebrated its 100-year anniversary with “Scripps Research Day,” as declared by the City of San Diego. The event marked a century of life-saving discoveries, while also looking toward the future of scientific achievement. Scripps Research President and CEO Pete Schultz and San Diego Mayor Todd Gloria gave remarks and shared the official city proclamation with Institute staff, scientists and students. Attendees enjoyed a photo booth, music, food, games and a historic archives booth presented by Scripps Research Library.

As we age, learn and grow over our lifetimes, the brain continually responds and adapts to what we experience. In this Front Row lecture, Scripps Research Chair of the Department of Neuroscience Hollis Cline revealed how sensory experiences shape the brain during development and aging—particularly visual experiences. Cline’s work has been critical in revealing how key visual brain circuits become disrupted in neurodevelopmental disorders, as well as in mapping the different communication pathways between neurons.

As Scripps Research celebrates our centennial, take a look at some of the major milestones over the past 100 years: from our founding in 1924, to our transformational leaders, and multiple Nobel Prize wins. Since its founding by philanthropist and journalist Ellen Browning Scripps in 1924, Scripps Research has remained at the forefront of science and medicine. Located in Torrey Pines, the institute now houses six research departments, multiple Nobel laureates and a top-ranked graduate school. Discoveries at Scripps Research have led to 15 approved medicines, including five invented within the institute’s labs. Scripps Research has also been an influential force in shaping the bioscience community atop the Torrey Pines Mesa, which is now a thriving and collaborative ecosystem of academic institutions, biopharmaceutical companies and nonprofit organizations. As Scripps Research enters a new century, the institute plans to expand its global impact on science and human health. Researchers will continue pursuing bold, transformative ideas, while translating these foundational discoveries into life-saving medicines. These are aimed at treating a spectrum of severe conditions, including cancer, neurological disorders, infectious diseases and much more.

In the inaugural lecture of the 2024 Centennial Front Row series, President and CEO Peter Schultz illuminated how Scripps Research is building on its storied past—a remarkable century of discovery and innovation—to establish a new paradigm for the future of science and medicine. Under Schultz’s leadership, Scripps Research is expanding its global impact by empowering exceptional scientists to pursue groundbreaking ideas and seamlessly blending curiosity-fueled science with impact-driven drug discovery. Schultz shared how this unique approach is already giving rise to a new generation of first-in-class medicines against cancers, heart disease, deadly pathogens, neurological disorders and many other health threats.

In 2024, Scripps Research celebrated 100 years of Science Changing Life. Since its founding by philanthropist and journalist Ellen Browning Scripps in 1924, Scripps Research has remained at the forefront of science and medicine with six research departments, multiple Nobel laureates and a top-ranked graduate school.

Ever wondered what goes on inside one of world's top scientific research institutes? Take a unique tour with this incredible flythrough of Scripps Research in La Jolla, California. Since 1924, Scripps Research has been at the forefront of uncovering biological insights, demystifying how our bodies work, and translating those discoveries into real-world impact. In 2024, the institute celebrated its centennial, a milestone that marked a century of seminal discoveries in immunology; infectious diseases (such as COVID, flu, HIV); neuroscience; heart disease; cancer; and more. The Institute has also made strides in groundbreaking chemistry advances, drug development and educational outreach efforts while contributing numerous findings that have improved human health around the world. Looking forward to the next 100 years of research, Scripps Research is committed to another century of Science Changing Life by advancing scientific understanding, educating the scientists of tomorrow, and impacting human health across the globe.

Innovation requires educating and training the next generation of scientific leaders. Since its founding in 1989, the Skaggs Graduate School of Chemical and Biological Sciences at Scripps Research has been ranked among the top 10 in the nation for PhD programs in Chemistry and Biological Sciences by U.S. News & World Report.

Calibr, a nonprofit research institute founded by Scripps Research President and CEO Pete Schultz, joined Scripps Research in 2018 as its drug discovery division. As a world-class nonprofit “bench to bedside” drug discovery engine, Calibr delivers groundbreaking solutions to unmet medical needs by uniting the creativity of fundamental discovery with highly focused R&D capabilities and expertise.